Literature DB >> 23157641

Synthesis and biological evaluation of low molecular weight fluorescent imaging agents for the prostate-specific membrane antigen.

Ying Chen1, Mrudula Pullambhatla, Sangeeta R Banerjee, Youngjoo Byun, Marigo Stathis, Camilo Rojas, Barbara S Slusher, Ronnie C Mease, Martin G Pomper.   

Abstract

Targeted near-infrared (NIR) optical imaging can be used in vivo to detect specific tissues, including malignant cells. A series of NIR fluorescent ligands targeting the prostate-specific membrane antigen (PSMA) was synthesized and each compound was tested for its ability to image PSMA+ tissues in experimental models of prostate cancer. The agents were prepared by conjugating commercially available active esters of NIR dyes, including IRDye800CW, IRDye800RS, Cy5.5, Cy7, or a derivative of indocyanine green (ICG) to the terminal amine group of (S)-2-(3-((S)-5-amino-1-carboxypentyl)ureido)pentanedioic acid 1, (14S,18S)-1-amino-8,16-dioxo-3,6-dioxa-9,15,17-triazaicosane-14,18,20-tricarboxylic acid 2 and (3S,7S)-26-amino-5,13,20-trioxo-4,6,12,21-tetraazahexacosane-1,3,7,22-tetracarboxylic acid 3. The K(i) values for the dye-inhibitor conjugates ranged from 1 to 700 pM. All compounds proved capable of imaging PSMA+ tumors selectively to varying degrees depending on the choice of fluorophore and linker. The highest tumor uptake was observed with IRDye800CW employing a poly(ethylene glycol) or lysine-suberate linker, as in 800CW-2 and 800CW-3, while the highest tumor to nontarget tissue ratios were obtained for Cy7 with these same linkers, as in Cy7-2 and Cy7-3. Compounds 2 and 3 provide useful scaffolds for targeting of PSMA+ tissues in vivo and should be useful for preparing NIR dye conjugates designed specifically for clinical intraoperative optical imaging devices.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23157641      PMCID: PMC4131203          DOI: 10.1021/bc3003919

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  40 in total

Review 1.  The clinical use of indocyanine green as a near-infrared fluorescent contrast agent for image-guided oncologic surgery.

Authors:  Boudewijn E Schaafsma; J Sven D Mieog; Merlijn Hutteman; Joost R van der Vorst; Peter J K Kuppen; Clemens W G M Löwik; John V Frangioni; Cornelis J H van de Velde; Alexander L Vahrmeijer
Journal:  J Surg Oncol       Date:  2011-04-14       Impact factor: 3.454

Review 2.  Optical imaging in cancer research: basic principles, tumor detection, and therapeutic monitoring.

Authors:  Metasebya Solomon; Yang Liu; Mikhail Y Berezin; Samuel Achilefu
Journal:  Med Princ Pract       Date:  2011-07-11       Impact factor: 1.927

3.  Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen.

Authors:  Sangeeta Ray Banerjee; Mrudula Pullambhatla; Youngjoo Byun; Sridhar Nimmagadda; Catherine A Foss; Gilbert Green; James J Fox; Shawn E Lupold; Ronnie C Mease; Martin G Pomper
Journal:  Angew Chem Int Ed Engl       Date:  2011-08-22       Impact factor: 15.336

4.  Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate.

Authors:  Takahito Nakajima; Makoto Mitsunaga; Neil H Bander; Warren D Heston; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2011-07-27       Impact factor: 4.774

5.  68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer.

Authors:  Sangeeta Ray Banerjee; Mrudula Pullambhatla; Youngjoo Byun; Sridhar Nimmagadda; Gilbert Green; James J Fox; Andrew Horti; Ronnie C Mease; Martin G Pomper
Journal:  J Med Chem       Date:  2010-07-22       Impact factor: 7.446

6.  Cancer statistics, 2012.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2012-01-04       Impact factor: 508.702

7.  Synthesis and biological analysis of prostate-specific membrane antigen-targeted anticancer prodrugs.

Authors:  Sumith A Kularatne; Chelvam Venkatesh; Hari-Krishna R Santhapuram; Kevin Wang; Balasubramanian Vaitilingam; Walter A Henne; Philip S Low
Journal:  J Med Chem       Date:  2010-11-11       Impact factor: 7.446

8.  Radical prostatectomy versus watchful waiting in early prostate cancer.

Authors:  Anna Bill-Axelson; Lars Holmberg; Mirja Ruutu; Hans Garmo; Jennifer R Stark; Christer Busch; Stig Nordling; Michael Häggman; Swen-Olof Andersson; Stefan Bratell; Anders Spångberg; Juni Palmgren; Gunnar Steineck; Hans-Olov Adami; Jan-Erik Johansson
Journal:  N Engl J Med       Date:  2011-05-05       Impact factor: 91.245

9.  A targeted low molecular weight near-infrared fluorescent probe for prostate cancer.

Authors:  Tiancheng Liu; Lisa Y Wu; Mark R Hopkins; Joseph K Choi; Clifford E Berkman
Journal:  Bioorg Med Chem Lett       Date:  2010-09-17       Impact factor: 2.823

10.  A low molecular weight PSMA-based fluorescent imaging agent for cancer.

Authors:  Ying Chen; Surajit Dhara; Sangeeta Ray Banerjee; Youngjoo Byun; Mrudula Pullambhatla; Ronnie C Mease; Martin G Pomper
Journal:  Biochem Biophys Res Commun       Date:  2009-10-08       Impact factor: 3.575

View more
  33 in total

1.  [(18)F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA).

Authors:  Xing Yang; Ronnie C Mease; Mrudula Pullambhatla; Ala Lisok; Ying Chen; Catherine A Foss; Yuchuan Wang; Hassan Shallal; Hannah Edelman; Adam T Hoye; Giorgio Attardo; Sridhar Nimmagadda; Martin G Pomper
Journal:  J Med Chem       Date:  2015-12-16       Impact factor: 7.446

2.  PSMA-targeted contrast agents for intraoperative imaging of prostate cancer.

Authors:  Kai Bao; Jeong Heon Lee; Homan Kang; G Kate Park; Georges El Fakhri; Hak Soo Choi
Journal:  Chem Commun (Camb)       Date:  2017-01-13       Impact factor: 6.222

3.  Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer.

Authors:  Ben T Copeland; Hassan Shallal; Chentian Shen; Kenneth J Pienta; Catherine A Foss; Martin G Pomper
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

Review 4.  The prostate-specific membrane antigen: lessons and current clinical implications from 20 years of research.

Authors:  Benjamin T Ristau; Denise S O'Keefe; Dean J Bacich
Journal:  Urol Oncol       Date:  2013-12-08       Impact factor: 3.498

5.  A PSMA-targeted theranostic agent for photodynamic therapy.

Authors:  Ying Chen; Samit Chatterjee; Ala Lisok; Il Minn; Mrudula Pullambhatla; Bryan Wharram; Yuchuan Wang; Jiefu Jin; Zaver M Bhujwalla; Sridhar Nimmagadda; Ronnie C Mease; Martin G Pomper
Journal:  J Photochem Photobiol B       Date:  2016-12-18       Impact factor: 6.252

6.  Development of targeted near-infrared imaging agents for prostate cancer.

Authors:  Xinning Wang; Steve S Huang; Warren D W Heston; Hong Guo; Bing-Cheng Wang; James P Basilion
Journal:  Mol Cancer Ther       Date:  2014-09-19       Impact factor: 6.261

7.  Translational Molecular Imaging of Prostate Cancer.

Authors:  Ana P Kiess; Steve Y Cho; Martin G Pomper
Journal:  Curr Radiol Rep       Date:  2013-09-01

8.  Salicylic Acid-Based Polymeric Contrast Agents for Molecular Magnetic Resonance Imaging of Prostate Cancer.

Authors:  Sangeeta Ray Banerjee; Xiaolei Song; Xing Yang; Il Minn; Ala Lisok; Yanrong Chen; Albert Bui; Samit Chatterjee; Jian Chen; Peter C M van Zijl; Michael T McMahon; Martin G Pomper
Journal:  Chemistry       Date:  2018-04-26       Impact factor: 5.236

9.  Fluorescently labeled therapeutic antibodies for detection of microscopic melanoma.

Authors:  Kristine E Day; Lauren N Beck; Nicholas L Deep; Joy Kovar; Kurt R Zinn; Eben L Rosenthal
Journal:  Laryngoscope       Date:  2013-04-24       Impact factor: 3.325

Review 10.  Prostate-specific membrane antigen as a target for cancer imaging and therapy.

Authors:  A P Kiess; S R Banerjee; R C Mease; S P Rowe; A Rao; C A Foss; Y Chen; X Yang; S Y Cho; S Nimmagadda; M G Pomper
Journal:  Q J Nucl Med Mol Imaging       Date:  2015-07-24       Impact factor: 2.346

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.